Skip to content


  • Meeting abstract
  • Open Access

PW02-040 - Low-penetrance NLRP3 variants

  • 1,
  • 1,
  • 2,
  • 3,
  • 4,
  • 5,
  • 6,
  • 7,
  • 8 and
  • 1
Pediatric Rheumatology201311 (Suppl 1) :A181

  • Published:


  • Conjunctivitis
  • Sensorineural Hearing Loss
  • Anakinra
  • Musculoskeletal Symptom
  • Autosomal Dominant Disease


Cryopyrin-associated periodic syndrome (CAPS) presents as rare, autosomal dominant disease spectrum, due to mutations in the NLRP3 gene which result in an excessive interleukin-1 (IL-1) release.

In patients with low-penetrance NLRP3 variants, the clinical presentation varies widely. So far, a correlation with a specific phenotype could not be demonstrated.


The aim of this study was to analyze the association of the V198M, R488K, and Q703K substitutions with a specific phenotype, laboratory markers, and the response to IL-1 inhibitors anakinra and canakinumab.


This multi-center observational study included 44 patients (25 children and 19 adults). All patients were symptomatic with some symptoms suggesting possible CAPS at the time of baseline examination. Genetic analysis detected one of the following NLRP3 variants: Q703K (n=18), R488K (n=6), and V198M (n=20).

Clinical phenotypes were described and laboratory markers were analyzed. In order to review the response to IL-1 inhibitors, data from follow-up visits were also evaluated.


At baseline examination, patients reported signs of systemic inflammation such as fever (75%), headache (73%), musculoskeletal symptoms (84%), and fatigue (77%). Other CAPS-specific features were rash (82%), conjunctivitis (43%), and sensorineural hearing loss (25%).

More than half of the patients (57%) reported abdominal pain and other gastrointestinal symptoms. A history of gastro-esophageal reflux was described by 23% of the patients, and 39% of the patients had oral ulcers.

Inflammation markers were only slightly increased: ESR was elevated in 26% (n=34) and C-reactive protein (CRP) in 38% (n=40).

Serum amyloid A (SAA) was raised in 36% (8/22) of the patients. Eight out of nine patients (89%) had elevated TNF-α-levels at baseline examination.

At baseline evaluation, 25 patients were treated with IL-1 inhibitors (anakinra or canakinumab). Data from follow-up visits during the first year of treatment were available from 21 patients: clinical disease activity was reduced in all cases; five patients (24%) achieved full remission, 13 (62%) still had mild symptoms, and three patients (14%) showed only a partial response.


Heterozygous carriers of NLRP3 variants V198M, R488K, and Q703K display distinct clinical characteristics compared to CAPS patients with definite disease causing mutations, including a high incidence of gastrointestinal symptoms, only slightly elevated inflammatory parameters, and a potentially inferior response to IL-1 inhibition.


Authors’ Affiliations

Department of Pediatrics, Division of Pediatric Rheumatology, University Hospital Tuebingen, Tuebingen, Germany
Translational Autoinflammatory Disease Section, NIAMS/NIH, Bethesda, MD, USA
Division of Rheumatology and Allergy/Immunology, University of California at San Diego, San Diego, CA, USA
Hämatologie, Onkologie u. Rheumatologie, Universitätsklinikum Heidelberg, Heidelberg, Germany
„Allergie-Centrum Charité“, Klinik für Dermatologie, Charité Campus Mitte, Berlin, Germany
Kinder- und Jugendrheumatologie, Clementine-Kinderhospital, Frankfurt, Germany
Abteilung für Allgemeine Kinder- und Jugendmedizin, Asklepios-Klinik Sankt Augustin, Sankt Augustin, Germany
Institut für Laboratoriumsmedizin und Humangenetik, Singen, Germany


© Endres et al; licensee BioMed Central Ltd. 2013

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.